SINGAPORE, May 20 (Xinhua) -- AstraZeneca will invest 1.5 billion U.S. dollars in building a manufacturing facility in Singapore for antibody drug conjugates (ADCs), the biopharmaceutical giant announced Monday.
AstraZeneca aims to begin design and construction of the manufacturing facility by the end of this year, with targeted operational readiness from 2029.
ADCs are next-generation treatments that deliver highly potent cancer-killing agents directly to cancer cells through a targeted antibody, according to the company. ■
